Piper Sandler initiated coverage of Taysha Gene Therapies with an Overweight rating and $9 price target. The company’s lead asset, TSHA-102 , is poised to transform the treatment paradigm for Rett syndrome a rare, genetic neurodevelopmental disorder with a high unmet need, despite the existence of an approved therapy, the analyst tells investors in a research note. With “further derisking data” anticipated near term, the stock is set to “inflect meaningfully higher” as soon as mid-2024, with additional drivers toward year-end, says Piper.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Taysha Gene Therapies announces inducement grant under Nasdaq listing rule
- Taysha Gene Therapies price target raised to $7 from $5 at Chardan
- Taysha Gene Therapies On Edge: The High Stakes of TSHA-102’s Regulatory Approval Journey
- Taysha Gene Therapies price target raised to $7 from $5 at Needham